Roche Unveils Positive Phase 3 Data in Breast Cancer Trial
A postsurgical chemotherapy regimen of Roche’s Perjeta (pertuzumab) plus Herceptin (trastuzumab) and chemotherapy cut the risk of death by 28 percent compared to Herceptin and chemo alone in patients with…